Generics Bulletin is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Brian Yang

Managing Editor

Beijing, China

Brian is in charge of overall China coverage within the APAC pharma news team. A veteran journalist, he has written extensively on R&D, regulatory, market access and business issues. Brian has led a team of writers providing industry-leading coverage in the second-largest health care market.

Latest From Brian Yang

China Biotech Podcast: BIOSECURE Updates, Genmab/ProfoundBio Deal

In this mixed Chinese- and English-language episode, guest speaker Treehill Partners co-founder Ali Pashadezah joins Brian Yang and Dexter Yan to discuss updates on the proposed BIOSECURE Act in the US Congress and US-China biotech movements. Also discussed is how Chinese biotechs are becoming acquisition targets for overseas biotech companies, including the recent purchases of Profound by Genmab and AnHeart Theraputics by Nuvantion.

China United States

BIOSECURE: What’s Coming Next?

The potential impact of the BIOSECURE Act continues to spread as the Biden administration increases its focus on China. But with BIO's top lobbyist and the top House sponsor of the legislation now headed out the door, the future of the bill remains uncertain.

China United States

China Implements Data Transfer Regulation, With Some Waivers

A newly enacted regulation in China governing the overseas transfer of data allows waivers under certain conditions but also introduces some new hurdles compared to the draft version.

China Compliance

China Localization – VBP Sees Global Medtechs Ponder Stay Or Exit

It is the time of year when global healthcare industry CEOs descend on China's capital to discuss strategies. A change of mood is evident among medtechs and pharmas.

China Policy

Stay Or Exit? Global Health Players Ponder New China Trajectory

It's again the time of year when global CEOs descend on China's capital to discuss strategies. This year, however, the mood is different.

China Business Strategies

Chinese Language Podcast: BIOSECURE Act, US PD-1 Approval, ADC Updates

Guest speaker and lawyer Kevin Duan joins Brian Yang and Dexter Yan to discuss the planned US BIOSECURE Act, the US approval of BeiGene's anti-PD-1 drug and the latest antibody-drug conjugates in development at Chinese pharma firms.

China United States
See All
UsernamePublicRestriction

Register